Difference between revisions of "WSI21-134"

From MGH Learn Pathology
(Created page with "{{dziOrderStudySet |order_date=July 06, 2021 01:07:32 PM |user=Em99 |class_name=Study Set |status=Created |collection_name=Cytopathology |class_type=Cytology |collection_topic...")
 
(Edited automatically from page WSI21-134.)
 
(77 intermediate revisions by 12 users not shown)
Line 1: Line 1:
−
{{dziOrderStudySet
+
{{ServiceRequest
−
|order_date=July 06, 2021 01:07:32 PM
+
|intent=order
−
|user=Em99
+
|category=409073007
−
|class_name=Study Set
+
|priority=routine
−
|status=Created
+
|code=study
−
|collection_name=Cytopathology
+
|orderDetail=order
−
|class_type=Cytology
+
|authoredOn=July 06, 2021 01:07:32 PM
−
|collection_topic=Pleural, Pericardial, and Peritoneal Fluids
+
|requester=Em99
−
|requested_by=IAC
+
|locationCode=learn
−
|restrict_access=Public
+
|access=public
 +
|subject=MGH
 +
|performer=MGH
 +
|supportingInfo=Cytology
 +
|requisition=Cytology
 +
|reasonCode=Pleural, Pericardial, and Peritoneal Fluids
 +
}}
 +
{{status
 +
|status=completed
 +
|identifier=WSI21-134
 +
|requester=Si787
 +
|authoredOn=March 10, 2022 10:38:21 AM
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-134
 +
|requester=Iac0
 +
|authoredOn=Jun 03, 2022 13:47:05
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-134
 +
|requester=Iac0
 +
|authoredOn=Jul 15, 2022 18:09:02
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-134
 +
|requester=Iac0
 +
|authoredOn=Jul 15, 2022 18:09:10
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-134
 +
|requester=Iac0
 +
|authoredOn=Jul 15, 2022 18:12:11
 +
}}
 +
{{status
 +
|status=received
 +
|identifier=WSI21-134
 +
|requester=Aja51
 +
|authoredOn=Jul 19, 2022 14:19:17
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-134
 +
|requester=Aja51
 +
|authoredOn=Jul 20, 2022 16:54:23
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-134
 +
|requester=Aja51
 +
|authoredOn=Jul 20, 2022 17:32:46
 +
}}
 +
{{status
 +
|status=received
 +
|identifier=WSI21-134
 +
|requester=Aja51
 +
|authoredOn=Jul 20, 2022 18:25:18
 +
}}
 +
{{status
 +
|status=scanning
 +
|identifier=WSI21-134
 +
|requester=Aja51
 +
|authoredOn=Jul 22, 2022 14:36:18
 +
}}
 +
{{status
 +
|status=completed
 +
|identifier=WSI21-134
 +
|requester=Aja51
 +
|authoredOn=Jul 22, 2022 14:36:48
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-134
 +
|requester=Ndk6
 +
|authoredOn=Sep 27, 2022 13:09:33
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-134
 +
|requester=Cfh13
 +
|authoredOn=Sep 27, 2022 17:05:55
 +
}}
 +
{{status
 +
|status=received
 +
|identifier=WSI21-134
 +
|requester=Rl391
 +
|authoredOn=Sep 28, 2022 11:22:35
 +
}}
 +
{{status
 +
|status=scanning
 +
|identifier=WSI21-134
 +
|requester=Aja51
 +
|authoredOn=Sep 30, 2022 14:30:49
 +
}}
 +
{{status
 +
|status=completed
 +
|identifier=WSI21-134
 +
|requester=Aja51
 +
|authoredOn=Oct 07, 2022 15:33:26
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-134
 +
|requester=Pab16
 +
|authoredOn=Oct 12, 2022 21:07:27
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-134
 +
|requester=Aja51
 +
|authoredOn=Oct 17, 2022 20:27:34
 +
}}
 +
{{status
 +
|status=received
 +
|identifier=WSI21-134
 +
|requester=Aja51
 +
|authoredOn=Oct 17, 2022 20:30:58
 +
}}
 +
{{status
 +
|status=scanning
 +
|identifier=WSI21-134
 +
|requester=Aja51
 +
|authoredOn=Oct 19, 2022 12:57:05
 +
}}
 +
{{status
 +
|status=completed
 +
|identifier=WSI21-134
 +
|requester=Aja51
 +
|authoredOn=Oct 24, 2022 17:35:59
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-134
 +
|requester=Ndk6
 +
|authoredOn=Nov 01, 2022 11:30:20
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-134
 +
|requester=Aja51
 +
|authoredOn=Nov 15, 2022 14:16:58
 +
}}
 +
{{status
 +
|status=received
 +
|identifier=WSI21-134
 +
|requester=Aja51
 +
|authoredOn=Nov 15, 2022 15:19:00
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-134
 +
|requester=Eh441
 +
|authoredOn=Nov 18, 2022 14:15:33
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-134
 +
|requester=Eh441
 +
|authoredOn=Nov 18, 2022 14:23:26
 +
}}
 +
{{status
 +
|status=received
 +
|identifier=WSI21-134
 +
|requester=Aja51
 +
|authoredOn=Dec 05, 2022 15:53:51
 +
}}
 +
{{status
 +
|status=scanning
 +
|identifier=WSI21-134
 +
|requester=Aja51
 +
|authoredOn=Dec 08, 2022 21:32:04
 +
}}
 +
{{status
 +
|status=completed
 +
|identifier=WSI21-134
 +
|requester=Aja51
 +
|authoredOn=Dec 13, 2022 19:52:11
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-134
 +
|requester=Cfh13
 +
|authoredOn=Feb 06, 2023 18:55:16
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-134
 +
|requester=Cfh13
 +
|authoredOn=Feb 06, 2023 19:01:40
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-134
 +
|requester=Cfh13
 +
|authoredOn=Feb 06, 2023 19:14:54
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-134
 +
|requester=Cfh13
 +
|authoredOn=Feb 06, 2023 19:16:48
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-134
 +
|requester=Cfh13
 +
|authoredOn=Feb 06, 2023 19:17:14
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-134
 +
|requester=Cfh13
 +
|authoredOn=Feb 06, 2023 19:21:42
 +
}}
 +
{{status
 +
|status=received
 +
|identifier=WSI21-134
 +
|requester=Aja51
 +
|authoredOn=Feb 08, 2023 14:17:31
 +
}}
 +
{{status
 +
|status=scanning
 +
|identifier=WSI21-134
 +
|requester=Aja51
 +
|authoredOn=Feb 09, 2023 17:52:56
 +
}}
 +
{{status
 +
|status=completed
 +
|identifier=WSI21-134
 +
|requester=Aja51
 +
|authoredOn=Feb 13, 2023 17:27:54
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-134
 +
|requester=Ez278
 +
|authoredOn=Feb 26, 2023 19:14:22
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-134
 +
|requester=Ez278
 +
|authoredOn=Feb 26, 2023 19:25:54
 +
}}
 +
{{status
 +
|status=received
 +
|identifier=WSI21-134
 +
|requester=Aja51
 +
|authoredOn=Mar 03, 2023 14:06:20
 +
}}
 +
{{status
 +
|status=scanning
 +
|identifier=WSI21-134
 +
|requester=Aja51
 +
|authoredOn=Mar 03, 2023 14:07:00
 +
}}
 +
{{status
 +
|status=completed
 +
|identifier=WSI21-134
 +
|requester=Aja51
 +
|authoredOn=Mar 03, 2023 14:08:31
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-134
 +
|requester=Cfh13
 +
|authoredOn=Mar 23, 2023 16:47:54
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-134
 +
|requester=Cfh13
 +
|authoredOn=Mar 23, 2023 16:56:22
 +
}}
 +
{{status
 +
|status=received
 +
|identifier=WSI21-134
 +
|requester=Aja51
 +
|authoredOn=Mar 28, 2023 12:59:08
 +
}}
 +
{{status
 +
|status=scanning
 +
|identifier=WSI21-134
 +
|requester=Aja51
 +
|authoredOn=Mar 28, 2023 12:59:54
 +
}}
 +
{{status
 +
|status=scanning
 +
|identifier=WSI21-134
 +
|requester=Aja51
 +
|authoredOn=Mar 28, 2023 13:00:59
 +
}}
 +
{{status
 +
|status=completed
 +
|identifier=WSI21-134
 +
|requester=Aja51
 +
|authoredOn=Apr 06, 2023 18:30:14
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-134
 +
|requester=Ndk6
 +
|authoredOn=Apr 13, 2023 20:04:39
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-134
 +
|requester=Aja51
 +
|authoredOn=May 15, 2023 12:43:08
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-134
 +
|requester=Mlz8
 +
|authoredOn=May 19, 2023 19:05:08
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-134
 +
|requester=Mlz8
 +
|authoredOn=May 19, 2023 19:08:00
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-134
 +
|requester=Iac0
 +
|authoredOn=May 25, 2023 20:12:03
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-134
 +
|requester=Mlz8
 +
|authoredOn=Sep 01, 2023 11:51:57
 
}}
 
}}

Latest revision as of 06:52, September 1, 2023


Request type Study
Subspecialty Cytology
Set Cytology
Topic Pleural, Pericardial, and Peritoneal Fluids
Presenter MGH


Toggle columns: Diagnosis

Case Clinical history Requester Diagnosis
Case Clinical history Requester Diagnosis

Case 1


18-year-old male. History of glioblastoma. Iac0 Metastatic glioblastoma.

Case 2


80yo M with left-sided pleural effusion Mlz8 Metastatic small cell lung carcinoma

Case 3


69yo F with pleural effusion Mlz8 Metastatic breast carcinoma (h/o invasive lobular carcinoma)

Case 4


48M • kidney failure. Pleura FNA. Iac0 Extramedullary hematopoiesis.

Case 5


Over 90-year old male with significant asbestos exposure Lcm51 Mesothelioma

Case 6


Pericardial effusion and history of parotid mass and atrial mass Mlz8 Metastatic Merkel cell carcinoma (from parotid primary)

Case 7


33F. Peritoneal carcinomatosis. Iac0 SMARCB1/INI1-deficient malignant epithelioid neoplasm.

Case 8


45 y/old F Long Hx of ESRD post kidney transplant. New effusion • duodenal mass and peritoneal nodules. Lcm51 PTLD • DLBCL type.

Case 9


41M. History of clear cell sarcoma of finger. Iac0 Metastatic clear cell sarcoma.

Case 10


73y/old F with right pleural effusion and flank pain. Aja51 Dx Epithelioid mesothelioma

Case 11


60 y/old F with new pleural effusion and prior "soft tissue" tumor in the arm. Aja51 Metastatic epithelioid hemangioendothelioma

Case 12


79 yo male Ndk6 Multiple myeloma

Case 13


50 yo female with history of metastatic carcinoma with bilateral pleural effusions Ndk6 Metastatic ovarian carcinoma • clear cell type

Case 14


65 yo M with a history of myeloma. Cfh13 Positive. Recurrent multiple myeloma to pleura.

Case 15


HISTORY OF MULTIPLE MYEOMA WITH PLASMACYTOMA. NOW HAS PLEURAL EFFUSIONS Pab16 Plasma cell myeloma

Case 16


78 YO male with h/o adenocarcinoma of pyloric antrum and ascites Ndk6 Metastatic adenocarcinoma c/w patient's known malignancy

Case 17


Hx triple negative breast cancer Est105 Metastatic breast carcinoma

Case 18


18-year-old man Eh441 Burkitt lymphoma

Case 19


55 yo F with a remote history of breast carcinoma. Cfh13 Metastatic adenocarcinoma • consistent with breast primary.

Case 20


55 yo M with chronic pleural effusion. Cfh13 Positive for malignant cells. Epithelioid hemangioendothelioma.

Case 21


52 yo F with acute respiratory failure in the setting of cocci and remote myeloma. Cfh13 Malignant cells present • consistent with involvement by the patient's known multiple myeloma.

Case 22


68yo man with a history of oncocytic thyroid carcinoma (metastatic to one lymph node) and clear cell renal cell carcinoma Ez278 Metastatic oncocytic carcinoma • consistent with spread from thyroid primary.

Case 23


68 yo woman with an ovarian mass Cfh13 Positive for metastatic ovarian serous carcinoma in a background of mucinous borderline tumor.

Case 24


73 yo man with ascites noted on surveillance following a Whipple for pancreatic carcinoma Cfh13 Malignant mesothelioma • epithelioid type.

Case 25


27 yo F with unrescetable thymic carcinoma Ndk6 Consistent with patient's known thymic carcinoma. Immunohistochemical studies show that the malignant cells are positive for p63 and CD5 • supporting the diagnosis.

Case 26


80-year-old man Njc35 Epithelioid mesothelioma.

Fibrosis and multinucleated giant cell reaction to polarizable foreign material • consistent with talc pleurodesis.

Note: Immunohistochemistry - tumor cells are positive for calretinin and WT1. They show loss of membranous/ cytoplasmic expression of merlin/NF2. They show retained expression of MTAP.

Case 27


49M • ascites fluid Mlz8 Metastatic gastric signet ring cell adenocarcinoma

Case 28


69F. Pleural based mass. Iac0 Epithelioid mesothelioma.

Case 29


73 yo male Dc679 Metastatic Ewing Sarcoma

Case 30


34 yo male with left empyema and c/f lymphoma Ndk6 High-grade B-cell lymphoma • consistent with Burkitt lymphoma

Case 31


75 yo male Ndk6 Atypical lymphoid cells present • consistent with involvement by mantle cell lymphoma

Case 32


72 yo female with thyroid cancer with recurrent right pleural effusion Ndk6 Metastatic carcinoma • consistent with the patient’s thyroid primary

Case 33


67F. Pelvic mass. Pelvic ascites. Iac0 Mucinous epithelium • consistent with involvement by ovarian mucinous neoplasm. Resection: borderline mucinous neoplasm.

Case 34


62F. History of papillary thyroid carcinoma. Now with pleural effusion. Iac0 Metastatic papillary thyroid carcinoma.

Case 35


20M. History of CNS lymphoma. Iac0 ALK-positive anaplastic large cell lymphoma (ALCL).

Case 36


87 YOF with with recurrent advanced pulmonary adenocarcinoma who recently developed myocarditis after Pembrolizumab and pleural effusion. Tz046 Metastatic adenocarcinoma.






























Retrieved from "https://learn.mghpathology.org/index.php?title=WSI21-134&oldid=113956"
  • Powered by MediaWiki
  • Search Powered by Cargo
  • Massachusetts General Hospital